Psoriasis Clinical Trials in Phoenix

Showing 181-200 of 213 trials

A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT02223039

This is a phase II, randomised, double-blind, placebo-controlled, multiple-dose, multi-center study of AbGn-168H in subjects with moderate to severe chronic plaque psoriasis. The objectives of this study is to investigate efficacy, safety, tolerability, and pharmacokinetics (PK) of multiple doses of AbGn-168H administered intravenously to patients with moderate to severe chronic plaque psoriasis.

Moderate to Severe Chronic Plaque Psoriasis

AbGenomics B.V Taiwan Branch50 participantsStarted May 2014

Phoenix, Arizona, United States • Rogers, Arkansas, United States • Ocala, Florida, United States +12 more locations

COMPLETED< 1 mile

A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)

NCT00096928

This was a multicenter, prospective, 5-year surveillance study of approximately 5000 Raptiva-treated patients and approximately 500 non-Raptiva treated patients (formerly 2500 comparison patients who were treated with a biologic therapy other than Raptiva) with chronic moderate to severe plaque psoriasis who were candidates for treatment with Raptiva.

Psoriasis

Genentech, Inc.1,846 participantsStarted Mar 2005

Birmingham, Alabama, United States • Daphne, Alabama, United States • Gadsden, Alabama, United States +179 more locations

A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis

A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)

Psoriasis Trials in Other Cities

A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Open Label Continuation Study in Moderate to Severe Psoriasis

Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis

Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens

Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index

A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents

Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Randomized Study of PH-10 for Psoriasis

Tofacitinib Ointment For Chronic Plaque Psoriasis

Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients

Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

An Exploratory Genetic Study in Participants With Psoriasis

Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris

A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118

Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis

A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis

Other Conditions in Phoenix